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RESUMO 
 
Introdução: A extração dentária está associada a modificações nos tecidos duros e moles. 
Estas alterações levam a uma diminuição da altura e do volume da crista alveolar com a sua atrofia. 
A reabilitação protética destas áreas pode constituir um desafio. No sentido de minimizar as 
modificações ósseas, diversos materiais têm sido apresentados. A utilização do osso de choco 
como material de preservação e regeneração óssea tem sido estudada. 
Objetivos: Pretendeu-se avaliar o potencial de regeneração óssea do osso de choco através 
da monitorização da atividade e diferenciação celulares de osteoblastos e osteoclastos.  
Materiais e métodos: A viabilidade das células estaminais mesenquimais humanas foi 
avaliada através dos testes da resazurina e Live/Dead. A biocompatibilidade foi testada usando 
resazurina, quando as células estavam em contacto direto com o material e quando o meio, que 
esteve em contacto com o material, foi adicionado às células. A distribuição das células nas 
amostras foi analisada através do staining da actina. A diferenciação das células estaminais em 
osteoblastos, nos blocos, foi avaliada em três experiências, fosfatase alcalina, Alizarin Red e Van 
Kossa. O tartrate-resistant acid phosphatase staining foi realizado para confirmar o 
desenvolvimento de osteoclastos a partir de monócitos/macrófagos, células percussoras 
adicionadas às amostras.  
Resultados: Os resultados do estudo mostraram a viabilidade das células estaminais 
mesenquimais humanas nas amostras. A adesão e migração celular ao longo das amostras parece 
ter ocorrido. A diferenciação dos osteoblastos nos blocos foi observada. A osteoclastogénese nas 
amostras parece ter ocorrido.  
Conclusão: As amostras apresentaram biocompatibilidade e permitiram a viabilidade, 
adesão, proliferação e diferenciação celular. Apesar da sua fragilidade, este biomaterial revelou 
propriedades interessantes que podem levar a considera-lo um excelente candidato para a 
preservação da crista alveolar e regeneração óssea.  
Em trabalhos futuros sugere-se a aplicação do material in vivo, utilizando um modelo 
animal similar à cavidade oral humana. 
Palavras-chave: osso de choco, células estaminais mesenquimais, regeneração óssea, 
preservação da crista alveolar. 
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ABSTRACT 
 
Introduction: Tooth extraction is associated to several changes in hard and soft tissues. 
The changes lead to a decrease of height and volume of alveolar ridge with atrophy. Prosthetic 
rehabilitation of this areas could be a challenge. In order to minimize bone modifications, several 
materials have been presented. The possibility of using cuttlefish bone as a bone preservation and 
regeneration material has been studied. 
Objectives: The aim of this study was to evaluate the potential of cuttlefish bone as a 
biomaterial with applications in bone regeneration by monitoring cell activity and differentiation 
in osteoblast and osteoclast.  
Materials and methods: The viability of mesenchymal stem cells in scaffolds was 
evaluated through resazurin reduction and Live/Dead assays. Biocompatibility was tested using 
resazurin, when the cells were in direct contact with the scaffolds and when the medium, which 
were in contact with the blocks, was added to the cells. Cells distribution in the scaffolds was 
analysed with the actin staining. Stem cells differentiation in osteoblasts, in the blocks, was 
evaluated with three different assays, Alkaline phosphatase, Alizarin Red and Van Kossa. Tartrate-
resistant acid phosphatase staining was performed to confirm osteoclasts development from 
monocyte/macrophage precursors cells added to the scaffolds. 
Results: The study results showed viability of the human mesenchymal stem cells in the 
scaffolds. Adhension and cellular migration into the samples seems to occur. Osteoblast 
differentiation in the blocks was observed. Osteoclastogenesis, in the samples, seems to occur.  
Conclusion: The scaffolds showed biocompatibility and allowed cells viability, adhension, 
proliferation and differentiation. Despite its brittleness, biomaterial revealed interesting properties 
which may lead to considering it an excellent candidate for alveolar ridge preservation and bone 
regeneration. 
In future works, is suggested in vivo studies, with an animal model similar to human oral 
cavity. 
Key Words: cuttlefish bone, mesenchymal stem cells, bone regeneration, alveolar ridge 
preservation. 
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INTRODUCTION 
 
After tooth extraction, a natural bone remodelling process begins (1-11), with most changes 
occurring in the first 3 months (8, 10, 12-16). In first 6 months post-extraction, is observed a mean 
reduction of 1.24 mm in height and 3.8 mm in width (3, 12, 17). Mandibular bone resorption is 
faster than on the maxillary bone (2, 8, 12), resorption in width is more significant than in height 
(1-4, 7, 8, 11-14, 16) and the buccal surface is the most affected (2-4, 7, 8, 12, 14). Prosthodontic 
rehabilitation with implants (1, 3-7, 14, 16) and tooth-supported prostheses may be compromised 
(2, 12). Achieving an optimal position of rehabilitation, especially with dental implants (3, 5, 10, 
12, 13) and the establishment of aesthetic and functional components could represent a challenge 
(1, 2, 5, 10, 18). To preserve, the bone level and the surrounding tissues, and prevent the necessity 
of tissue grafting, alveolar ridge preservation (ARP) should be considered a key component (1, 4, 
6-9, 12, 16, 17, 19).    
ARP consists in arresting or minimising the alveolar ridge resorption, after tooth extraction, 
maintaining bone architecture for future prosthodontic treatment, with/without dental implants (7, 
12-14). ARP techniques include: grafting materials (3, 4, 6, 8, 10, 13, 17-19), with/without the use 
of membranes (2-4, 12, 17, 19). Recent studies have shown a significantly less reduction in 
alveolar ridge in vertical and horizontal dimensions, after ARP, comparing with natural socket 
healing (2, 4, 6, 10, 12, 13, 15). Nonetheless, some alveolar bone resorption still occurs (2-4, 6, 8, 
10, 13, 15, 17).  
Autogenous bone graft is obtained and applied in the same individual (2, 3, 8). The “gold 
standard” material for bone graft (3, 5, 8-10, 20-23), it demonstrates osteogenic (3, 5, 8, 10, 15), 
osteoinductive and osteoconductive potential (3, 5, 8). However, autogenous bone graft applied in 
the socket shows fast resorption rate (3, 5) and a reduction of osteoconduction (3). Several studies 
have shown that, when applied to extraction sockets, autologous bone chips behave the same as in 
sites without graft (3). Other limitations are the restricted graft availability, the morbidity (5, 8, 9, 
20-24), complications associated to the donor site (5, 8, 9, 23), increased cost and operating time 
(8, 9). To overcome these limitations, other types of bone substitutes have been proposed (5, 9, 20, 
21, 23). 
Xenograft is obtained from a donor of non-human species (2, 3, 5, 8, 9). These 
osteoconductive materials suffer an organic components removal (2, 5), preventing immunogenic 
reactions (5). The inorganic mineral composition and the original architecture of the bone are 
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preserved (5). The slow resorption presented by xenografts (1, 5, 8, 10) allows their long stability 
(5) and the graft replacement by new formed bone (1).  
Allografts are from members of same species (3, 8, 9) but genetically dissimilar (2, 8, 9). 
Presenting osteoconductive properties (2, 5, 8, 9) only a few shows osteoinductivity (8, 9, 15). 
Second surgical donor site is not needed and is readily available (1, 8). The major limitation is the 
immunologic response to graft protein content or risk of cross-infection which could allow disease 
transmission (5, 8, 15, 24). 
Alloplast are synthetical graft materials (3, 5, 8, 9) or derived from a foreign inert source (2, 
8). In these group of osteoconductive materials (10, 15) are included hydroxyapatite, tricalcium 
phosphate, some polymers and bioactive glass (2, 5, 8, 9). Disadvantages are a nonoptimal 
physiologic bone turnover (8), some present fragility and poor fatigue (9). 
Despite all of the mentioned disadvantages, ARP procedures also add greater cost to the 
patient (11, 15). Therefore, is essential to find an alternative ARP material which low cost dues 
allows a systematic utilization in most of the dental extractions with a view to a later rehabilitation 
of the edentulous space. 
Cuttlebone (CB) consists in the internal skeleton of cuttlefish (16, 21, 22, 24-26). This 
inexpensive and worldwide available (16, 22, 27-30) biomaterial presents a unique interconnective 
(16, 22, 25, 28, 29, 31-33) and highly porous structure, essentially composed of calcium carbonate 
(16, 20-23, 25, 26, 29, 32, 34-37). In order to find potential bone substitutes, several studies have 
analysed hydrothermal transformation (HT) of calcium carbonate from natural aragonite 
(𝑝𝑜𝑙𝑦𝑚𝑜𝑟𝑝ℎ 𝑜𝑓 𝐶𝑎𝐶𝑂3) to hydroxyapatite (16, 20-25, 27-30, 32-38). After HT, CB presents an 
analogous crystallography and chemical composition to corals, which is similar to mineralized 
structure of natural bones (16, 21-24, 27-30, 33, 35). CB may have potential application as a 
scaffold in bone regeneration and ARP (16, 36, 38). 
The aim of this study was to evaluate the potential of CB as a bone regeneration biomaterial 
by analysing the cell activity and differentiation, the response of CB in osteoblast and osteoclast.  
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MATERIALS AND METHODS 
 
1. Preparation of cuttlefish bone blocks 
Preparation of scaffolds was done by Materials and Ceramic Engineering Department, 
University of Aveiro. CB was removed from cuttlefish (Sepia officinalis, from Atlantic Sea), 
cleaned with running water and air-dried. The samples were cut into blocks of 4 x 4 x 3 mm3 
(approximately). Some of these blocks, cuttlefish bone -  hydroxyapatite scaffold (CBHAS), were 
submitted at hydrothermal treatment transforming calcium carbonate in HA. Both cuttlefish bone 
scaffold (CBS) and CBHAS were sterilized, by autoclave, prior to be used in vitro.  
To optimize experimental protocols and achieve technical capacities in cell cultures, before 
using a co-culture model, human mesenchymal stem cells (hMSCs), osteoblasts and osteoclasts 
cultures were initially performed. Osteoblasts and osteoclasts co-cultures are technically more 
difficult to perform.  
 
 
2. Mesenchymal stem cell culture 
All cell culture procedures were performed under aseptic conditions. Cells were expanded 
into 75 mL culture flasks and maintained in DMEM complete at 37 ºC in an incubator with 5% 
𝐶𝑂2. In this study, the culture medium was refreshed every 2-3 days and were used cells of 
passages 9-11. When confluence was reached, hMSC were trypsinized from the flasks. 
 
 
3. Viability  
To evaluate the viability of the cells incubated in scaffolds, resazurin reduction assay was 
performed at days 1, 3 and 7, using 10% Resazurin. In all experiments, 2D wells and control wells 
were in 96 well-plates. The plates were protected from the light. Fluorescence was measured using 
Synergy™ Mx Monochromator-Based Multi-Mode Microplate Reader (𝜆𝑒𝑥 = 530 𝑛𝑚, 𝜆𝑒𝑚 =
590 𝑛𝑚). Three different experiments were performed: 
 
3.1. Optimization experiment without scaffolds  
To each well were added hMSCs (1x 104 cells) and 100  
𝜇𝐿 of DMEM complete and incubated at 37 ºC with 5% 𝐶𝑂2. In control wells, only 100 𝜇𝐿 of 
medium was added (no cells). 
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Resazurin (11 𝜇𝐿) was added to each well and incubate for 3h at 37 ºC with 5% 𝐶𝑂2. 
Then, 100 𝜇𝐿 of each well content was transferred to the correspondent well in 96 well 
microplates for fluorescence and the signal was recorded. 
 
3.2. Optimization experiments with scaffolds 
CBS and CBHAS were transferred into respective well of 96 well-plate. Scaffolds were 
maintained in 200  
𝜇𝐿/well of DMEM complete for 30 min. at 37 ºC in an incubator with 5% 𝐶𝑂2, to promote cellular 
adhesion. Medium was removed and hMSCs (1x 104 cells) were loaded on CBS, CBHAS and on 
2D wells for 30 min. at 37 ºC in an incubator with 5% 𝐶𝑂2. After the referred period of time, was 
added 200 𝜇𝐿/well of DMEM complete and incubated. In control wells, only 200 𝜇𝐿/well of 
medium was added (no cells). 
Resazurin (22 𝜇𝐿) was added to each well and incubate for 3h at 37 ºC with 5% 𝐶𝑂2. Then, 
only 100 𝜇𝐿 of each well content was transferred to the correspondent well in 96 well microplates 
for fluorescence and the signal was recorded at day 1 and 7.  
The experiment was repeated twice. However, cells were allowed to adhere to the blocks 
and 2D wells for a longer period of time (2h) and the assay was performed at days 1, 3 and 7. 
 
3.3. Resazurin reduction assay with scaffolds using non-treated multidishes for 
suspension cell culture (48 wells-plate) 
CBS and CBHAS were transferred into respective well of 48 well-plate to avoid cell 
adhesion at the bottom of the well. To promote cellular adhesion at the samples, scaffolds were 
maintained in 400  
𝜇𝐿/well of DMEM complete for 30min. at 37 ºC in an incubator with 5% 𝐶𝑂2. Medium was 
removed and hMSCs (1x 104 cells) were loaded on CBS, CBHAS and 2D wells for 2h at 37 ºC in 
an incubator with 5% 𝐶𝑂2. Then, 400 𝜇𝐿 and 200 𝜇𝐿 of DMEM complete were added to each 
CBS, CBHAS and 2D wells, respectively, and incubated at 37 ºC with 5% 𝐶𝑂2. In control wells, 
no cells were added, only 200 𝜇𝐿/well.  
To each well was added 44 𝜇𝐿 (48 well-plate) or 22 (96 well-plate) of resazurin and 
incubate for 3h at 37 ºC with 5% 𝐶𝑂2. Then, just 100 𝜇𝐿/well was transferred to the correspondent 
well in 96 well microplates for fluorescence. The fluorescent signal was analysed. 
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4. Live/Dead assay 
Cell viability was determined, not only with resazurin reduction assay but also using 
Live/Dead assay with Calcein and Propidium Iodide. Nuclei staining dye PI only achieve the 
nucleus of dead cells, emitting red fluorescence (𝜆𝑒𝑥 = 535 𝑛𝑚, 𝜆𝑒𝑚 = 617 𝑛𝑚). 
Simultaneously, staining with green-fluorescent, calcein-AM indicates intracellular esterase 
activity presented in live cells (𝜆𝑒𝑥 = 490 𝑛𝑚, 𝜆𝑒𝑚 = 515 𝑛𝑚).  
 
4.1. Optimization experiment without scaffolds 
Medium was removed and each well was gently washed with 100 𝜇𝐿 of PBS. Ca solution, 
containing 1 Ca:5000 PBS, was added to each well and incubate at room temperature, protected 
from the light, for 20min. After removing Ca solution, each well was washed with 100 𝜇𝐿 of PBS. 
PI solution, containing 1 PI:500 PBS, was added to the wells and incubate at room temperature, 
protected from the light, for 5min. Once, PI solution was removed, the wells were washed with 
100 𝜇𝐿 of PBS and analysed with inverted fluorescent microscope (Carl Zeiss, Germany) coupled 
to a camera AxioCam HRc. 
 
4.2. Optimization experiment with scaffolds 
Both typed of scaffolds were transferred into the respective well of 96 well-plate. The 
samples were maintained in 200  
𝜇𝐿/well of DMEM complete for 30 min. at 37 ºC in an incubator with 5% 𝐶𝑂2, to promote cellular 
adhesion. Medium was removed and hMSCs (1x 104 cells) were loaded on CBS, CBHAS and on 
2D wells for 30 min. at 37 ºC in an incubator with 5% 𝐶𝑂2. Then, 200 𝜇𝐿/well of DMEM complete 
was added and incubated. 
Live/Dead protocol, described in 4.1., was repeated using CBS and CBSHA and 200 
𝜇𝐿/well of PBS instead 100 𝜇𝐿/well. 
 
4.3. Live/Dead assay with scaffolds using non-treated multidishes for suspension cell 
culture (48 wells-plate) 
CBS and CBHAS were transferred into respective well of 48 well-plate to avoid cell 
adhesion at the bottom of the well. In order to allow cellular adhesion at the samples, scaffolds 
were maintained in 400  
𝜇𝐿/well of DMEM complete for 30min. at 37 ºC in an incubator with 5% 𝐶𝑂2. Medium was 
removed and hMSCs (1x 104 cells) were loaded on CBS, CBHAS wells in 48 wells-plate and 2D 
wells in 96 wells-plate for 2h at 37 ºC in an incubator with 5% 𝐶𝑂2. Then, 400 𝜇𝐿 and 200 𝜇𝐿 of 
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DMEM complete were added to each CBS, CBHAS and 2D wells, respectively, and incubated at 
37 ºC with 5% 𝐶𝑂2. At day 1, scaffolds were moved to the 96 wells-plate and Live/Dead protocol 
used in 4.2. were performed.  
 
 
5. Biocompatibility  
In order to evaluate biocompatibility two cell culture assays were used:  
 
5.1. Direct contact 
Tested in resazurin reduction assay described previously. 
 
5.2. Elution method 
In elution method the cellular response to medium, which was previously in contact with 
the material, is analysed.  
CBS and CBHAS were transferred to 96 well-plate. Scaffolds were maintained in 200  
𝜇𝐿/well of DMEM complete for 7 days at 37 ºC in an incubator with 5% 𝐶𝑂2. Then, medium from 
samples were collected in different eppendorf’s and frozen at -80 ºC.  
hMSCs (1x 104 cells) were loaded to each well and incubate for 2h at 37 ºC in an incubator 
with 5% 𝐶𝑂2, to allow cells adhesion to the bottom of the wells. Thawed medium was applied 
(200 𝜇𝐿/well). At days 3 and 7 resazurin reduction assay was performed adding 22 𝜇𝐿/well of 
resazurin and incubate for 3h at 37 ºC with 5% 𝐶𝑂2. Then, the fluorescent signal was recorded. At 
day 3, after resazurin reduction assay, the culture medium was replaced by new thawed medium.   
 
 
6. Cell distribution into the scaffold 
In order to observe cell adherence, distribution and proliferation into the blocks, actin 
staining was performed. Prior to staining, scaffolds were washed twice with 200 𝜇𝐿/well of PBS, 
cells were fixed with 200 𝜇𝐿/well of 4% PFA for 10 min and washed again with 200 𝜇𝐿/well of 
PBS. Two different analyses were done using CBS and CBHAS from days 1, 3 and 7 – using the 
scaffolds and using thick sections of 5 𝜇𝑚 from the scaffolds. The standard protocols were as 
follows.  
 
6.1. Actin Staining in scaffolds 
To promote membrane permeabilization 200 𝜇𝐿/well of 0.1% Triton was loaded, for 5min. 
at room temperature. After removing Triton, the samples were washed with 200 𝜇𝐿/well of PBS. 
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To block cells was added 200 𝜇𝐿/𝑤𝑒𝑙𝑙 of 1% BSA and incubated for 30min. at 37 ºC with 5% 
𝐶𝑂2. Subsequently, samples were washed with 200 𝜇𝐿/well of PBS and 200 𝜇𝐿/well of Alexa 
Fluor 488 phalloidin (Invitrogen, USA) containing 1 Alexa Fluor 488 phalloidin:100 PBS was 
added to each well for 20min. at room temperature (protected from the light). Samples were 
washed with 200 𝜇𝐿/well of PBS and 200 𝜇𝐿/well of Hoescht (Invitrogen, USA) containing 1 
Hoescht:1000 PBS was added, for 5min. at room temperature (protected from light). Samples were 
washed with 200 𝜇𝐿/well of PBS and images were obtained with inverted fluorescent microscope 
(Carl Zeiss, Germany) coupled to a camera AxioCam HRc. 
 
6.2. Actin Staining in scaffold’s sections 
Each microscope slide was washed with 1mL of PBS. To achieve membrane 
permeabilization, 50 𝜇𝐿 𝑝𝑒𝑟 𝑚𝑖𝑐𝑟𝑜𝑠𝑐𝑜𝑝𝑒 𝑠𝑙𝑖𝑑𝑒 of 5% BSA + TBST were loaded for 30min. at 
the room temperature. Slides were washed with 1mL of PBS. Then, 50 𝜇𝐿/slide of Alexa Fluor 
488 phalloidin (Invitrogen, USA) containing 1 Alexa Fluor 488 phalloidin:100 PBS was added to 
each slide for 40min. at room temperature (protected from the light). Microscope slides were 
washed with 1mL of PBS and 50 𝜇𝐿/slide of Hoescht (Invitrogen, USA) containing 1 
Hoescht:1000 PBS was added for 5min. at room temperature (protected from the light). Samples 
were washed with 1mL of PBS and analysed at inverted fluorescent microscope (Carl Zeiss, 
Germany) associated to a camera AxioCam HRc. 
This procedure was repeated with Alexa Fluor 594 Phalloidin (Invitrogen, USA) instead 
Alexa Fluor 488 phalloidin. To each microscope slide was added 50 𝜇𝐿/slide of Alexa Fluor 594 
Phalloidin (Invitrogen, USA) containing 1 Alexa Fluor 594 Phalloidin:40 PBS for 1h at room 
temperature (protected from the light). 
 
 
7. Osteoblast differentiation 
 In order to induce osteoblast differentiation of hMSC, cells were cultured in medium 
supplemented with an OS (100 𝜇𝑀 dexamethasone, 1 M 𝛽-glycerophosphate and 1.6 mg/mL 
ascorbic acid). During the experimental period, the OS-containing media was changed every 2-3 
days.  
CBS and CBHAS were transferred into respective well of 96 well-plate. Scaffolds were 
maintained in 200  
𝜇𝐿/well of DMEM complete for 30 min. at 37 ºC in an incubator with 5% 𝐶𝑂2, to promote cellular 
adhesion. Medium was removed and hMSCs (1x 104 cells) were loaded on CBS, CBHAS and on 
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2D wells for 2h at 37 ºC in an incubator with 5% 𝐶𝑂2. Then, was added 200 𝜇𝐿/well of DMEM 
complete to control wells and 200 𝜇𝐿/well of DMEM complete supplemented with an OS to 
differentiation wells and incubated. 
 
7.1. ALP activity assay 
In order to prove hMSC differentiation in osteoblasts, ALP activity assay was performed. 
During differentiation, osteoblasts express ALP. However, ALP is not limited to osteoblasts and 
so, it is essential to do Alizarin Red and Van Kossa Satining. The ALP assay was done at days 7 
and 14 of hMSC osteogenic differentiation.  
The culture plates were removed from the incubator and the medium was replaced by 200 
𝜇𝐿/well of PBS. After removing PBS, 200 𝜇𝐿/well of 4% PFA solution was added and the plates 
incubate for 15min. at 4 ºC. Then, all wells were washed with 200 𝜇𝐿/well of distilled and 
deionized water, which left for 1min. The process was repeated but leaving the water for 15min. 
AP solution, containing Fast Violet and Naphtol (in proportion 1:0.04), was prepared and 200 𝜇𝐿 
was added to each well. The plate was protected from the light and incubated at room temperature 
for 45min. After this time, all wells were gently washed twice with 200 𝜇𝐿/well of distilled and 
deionized water. The water was removed and the plates were checked under the stereomicroscope 
(SZX10, Olympus, Center Valley, PA, USA) connected to a digital camera (DP21, Olympus). 
 
7.2. Alizarin Red Staining 
During mineralization, osteoblasts can be induced to produce vast extracellular calcium 
deposits, which can be stained by Alizarin Red S. Calcium deposits represent a positive 
indication of in vitro bone formation and will be stained orange-red. Alizarin Red Staining was 
performed at days 14 and 21 of hMSC osteogenic differentiation. 
After culture medium was removed, wells were washed twice with 200 𝜇𝐿/well of distilled 
and deionized water. Then, cells were fixed in ice-cold 70% ethanol for 1h at -20 ºC. The ethanol 
was removed and wells were allowed to air dry. All wells were washed twice with 200 𝜇𝐿/well of 
distilled and deionized water and the satin was eluted with 10% (w/v) CPC, containing 10g CPC 
diluted in 100 mL of 10 mM of 𝑁𝑎2𝑃𝑂4 solution (dilute 0.142 g of 𝑁𝑎2𝑃𝑂4 in 100 mL of distilled 
and deionized water), at the rotatory shaker for 20min. with gentle agitation. The samples were 
photographed under the stereomicroscope (SZX10, Olympus, Center Valley, PA, USA) coupled 
to a digital camera (DP21, Olympus) and the absorvence was measure at 570 nm, comparing to 
alizarin red standard curve. 
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7.3. Van Kossa Staining 
Van Kossa Satining is not specific for the calcium ion, revelling calcium or calcium salt 
deposits. The cells are treated with a silver nitrate solution and the replacement of reduced calcium 
by silver occurs visualized as metallic silver. Van Kossa Staining was performed at days 14 and 
21 of hMSC osteogenic differentiation. 
In brief, culture plates were removed from the incubator and the medium was replaced by 
200 𝜇𝐿/well of PBS. After removing PBS, 200 𝜇𝐿/well of 4% PFA solution was added and the 
plates incubate for 15min. at 4 ºC. Then, all wells were washed with 200 𝜇𝐿/well of distilled and 
deionized water, which was left for 1min. The referred procedure was repeated, leaving the water 
for 15min. The 2.5% silver nitrate solution was added (200 𝜇𝐿/well) and the plates were placed 
under ultra-violet light for 30min. After rinsed with 200 𝜇𝐿/well of distilled and deionized, 200 
𝜇𝐿/well of 5% sodium thiosulfate solution was added for 2min. The wells were gently washed 
with 200 𝜇𝐿/well of distilled and deionized water and checked under the stereomicroscope 
(SZX10, Olympus, Center Valley, PA, USA) coupled to a digital camera (DP21, Olympus). 
 
 
8. Monocyte culture 
The primary human monocytes culture was obtained from human donor blood as 
previously reported (39). Cells were isolated and maintained in α-MEM (Gibco, Thermo Fisher 
Scientific, USA) containing 10% FBS and 1% P/S for 7 days, at 37 ºC in an incubator with 5% 
𝐶𝑂2. 
 
 
9. Osteoclast induction (Osteoclastogenesis) 
To induce expression of genes that characterize the osteoclast lineage and promote the 
development of mature osteoclasts from monocyte/macrophage precursors cells, CSF-1 and 
RANKL are required.   
Cells were maintained 2 days in α-MEM (Gibco, Thermo Fisher Scientific, USA) 
containing 25ng/mL M-CSF (PeproTech, USA) and 5 days in α-MEM (Gibco, Thermo Fisher 
Scientific, USA) containing 25ng/mL M-CSF (PeproTech, USA) and 25ng/mL RANKL 
(PeproTech, USA) at 37 ºC in an incubator with 5% 𝐶𝑂2. In this study, the culture medium was 
refreshed every 2-3 days. 
 
 
 
12 
 
9.1. TRAP Staining 
TRAP is expressed by osteoclasts. Following the manufacturer’s instructions, an Acid 
phosphatase, Leukocyte (TRAP) kit (Sigma-Aldrich) was used. Images were obtained using a 
stereomicroscope (SZX10, Olympus, Center Valley, PA, USA) associated to a digital camera 
(DP21, Olympus).  
 
 
10. Statistical analysis 
The results are presented as mean ± standard error of the mean (SEM). Statistical analysis 
was performed using one-way and two-way ANOVA and Student’s t-test. Statistical significance 
was considered as p < 0.05. 
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RESULTS 
 
3. Viability  
3.1. Optimization experiment without scaffolds  
Resazurin values show a decrease corresponding to a reduction in cells metabolic activity 
in days 1, 4 and 7 (Fig. 1). The referred aspect could be explained by the decrease of free space 
for cell expansion and for some arbitrary factors. However, this experiment was performed in order 
to optimize the subsequence experiments and the technical issues associated to cell manipulation.   
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Fig.  1. Viability of hMSCs at days 1, 3 and 7. Data is expressed as mean ± SEM. 
**p<0.01, ****p<0.0001 
3.2. Optimization experiments with scaffolds 
In order to optimize the experiments with the scaffolds and the technical issues associated 
to cell and scaffolds manipulation, optimization experiments with scaffolds were performed. The 
values of resazurin assays are not presented due the lack of normalization factors, which could 
allow the comparison between 2D and 3D results. 
 
3.3. Resazurin reduction assay using non-treated multidishes for suspension cell 
culture (48 wells-plate) 
As shown in Fig. 2, no statistical differences are observed between 2D, CBS and CBSHA 
in days 1, 3 and 7. This result supports the idea of viability of the cells in CBS and CBSHA. 
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Fig.  2. Viability of hMSCs cultured on CBS and CBSHA after 1, 3 and 7 days in culture. 
Data is expressed as mean ± SEM. 
4. Live/Dead assay 
4.1. Optimization experiment without scaffolds 
The fluorescence images show huge number of live cells with some few dead cells (Fig. 
3). This experiment was performed in order to optimize subsequence experiments and technical 
issues associated to cell manipulation. 
 
 
 
 
 
 
 
4.2. Optimization experiment with scaffolds 
The results of live/dead assay images show live and dead cells in the surface of both 
scaffolds (Fig. 4). However, due the short period of time used for cells adherence to the samples 
(30 min.) a vast number of cells were found in the bottom of the wells. This experiment allowed 
the optimization of the live/dead protocol when using CBS and CBSHA.  
 
 
 
 
A B C 
Fig.  3. Live/Dead, day 1. Live cells are staining in green and dead cells presented in red. 
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4.3. Live/Dead assay with scaffolds using non-treated multidishes for suspension cell 
culture (48 wells-plate) 
The resultant images reveal scaffolds fluorescence, which proves unfeasible for the 
detection of fluorescence of the cells in the surface of the samples (Fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A
 
B 
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A
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Fig.  4. Representative images of Live/Dead with scaffolds, day 1. A: 
CBS. B: CBSHA. C: Cells in the bottom of the well of CBS. D: Cells in 
the bottom of the well of CBSHA. 
Fig.  5. Representative images of Live/Dead with scaffolds using non-
treated multidishes for suspension cell culture, day 1. A: CBS. B: 
CBSHA. 
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5. Biocompatibility 
5.1. Direct contact  
The results are presented in viability results (section 3.3.) where no differences were found 
between conditions. 
 
5.2. Elution method 
Statistical differences are observed between 2D and CBSM at day 3 with a high resazurin 
level in CBSM (Fig. 6). Moreover, concerning day 7, these differences are equally significant and 
are observed between 2D and CBSM, 2D and CBSHAM, CBSM and CBSHAM, with CBSM 
achieving the highest resazurin value followed by CBSHAM. The results presented seem to show 
that both, CBSM and CBSHAM, may increase cells metabolic activity.  
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Fig.  6. Elution method - Viability of cells cultured on CBSM and CBSHAM after 3 and 7 
days in culture. Data is expressed as mean ± SEM. *p<0.05, **p<0.01, ****p<0.0001 
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6. Cell distribution into the scaffold 
6.1. Actin Staining in scaffolds 
The attachment of the cells to the scaffolds were observed with the Actin Staining (Fig. 7). 
The cells cytoskeleton is stained in green and the nuclei is observed stained in blue. 
 
 
 
 
 
 
 
 
 
 
 
 
6.2. Actin Staining in scaffold’s sections 
The fluorescence images of day 1 demonstrated hMSCs attached to CBS and CBSHA 
(Fig. 8). In Fig. 9, cells are attached to the scaffolds at day 7 and cells position in different 
parallel sheets seems to show cells migration into the samples. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A B C 
Fig.  7. Representative images of Actin Staining showing Human mesenchymal stem cells attached to the 
scaffolds, day 7 (x40 A, x40 B and x10 C) 
Fig.  8. Representative images of Actin Staining in scaffold's sections of 
day 1 (x10 A and x10 B). A: CBSHA. B: CBS. Dashed line: define the 
approximate limit of the scaffolds. 
A B 
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7. Osteoblast differentiation 
7.1. ALP activity assay 
Intensive staining was seen in differentiation wells compared with the controls (Fig. 10 and 
Fig. 11). When comparing the results at day 7 and day 14, an increase of the staining is presented 
at day 14. The hMSC differentiation in osteoblast occurred and scaffolds seems to allow this 
process.  
 
Fig.  10. Representative wells of ALP activity assay at day 7 
Fig.  9. Representative images of Actin Staining in scaffold's section of day 7 (x10 A1, cells in detail in A2 
and x10 B). A1: CBSHA. A2: CBSHA. B: CBS. Dashed line: define the approximate limit of the scaffolds. 
A1 A2 B 
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Fig.  11. Representative wells of ALP activity assay at day 14 
 
7.2.Alizarin Red Staining 
The representative graph of Alizarin Red in 2D wells shown higher values of extracellular 
calcium deposits in differentiation wells, when compared with control wells (Fig. 12). The referred 
results proved that the differentiation of hMSCs in osteogenic cells occurred with a significant 
expression in differentiation wells, in comparison with control wells. The representative images 
(Fig.13) of this staining revealed a significant difference between 2D wells (differentiation and 
control). Intensive red stain, showing calcium deposits, is presented in 2D differentiation wells 
which contrast with the stain in 2D control well. The wells with scaffolds showed a complete stain 
of the blocks due to its calcium composition. This result does not allow any conclusions about 
hMSCs differentiation in scaffolds. 
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Fig.  12. Alizarin Red Staining performed in 2D at 
day 14. Data is expressed as mean ± SEM. 
*p<0.0007 
 
 
 
 
 
Fig.  13. Representative wells of Alizarin Red Staining at days 14 and 21 
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7.3. Van Kossa Staining 
The images obtained from Van Kossa Staining (Fig. 14) were consistent with the results 
obtained in Alizarin Red Staining. The 2D differentiation wells showed a metallic silver deposit, 
correspondent to calcium deposits, which proved the osteogenic differentiation of hMSCs. In 
contrast, in 2D control wells no deposit is visible. The wells with scaffolds showed a complete 
stain of the blocks with the metallic silver deposit due to its composition of calcium. This result 
does not allow any conclusions about hMSCs differentiation in scaffolds. 
 
 
Fig.  14. Representative wells of Van Kossa Staining at days 14 and 21 
 
8. Osteoclast induction 
8.1. TRAP Staining 
Multinucleated TRAP-positive cells (osteoclasts) are presented in the surface of the 
scaffold and in the bottom of the wells (Fig. 15 and Fig. 16) suggesting that osteoclastogenesis 
occurred. However, they are hard to visualize and so additional tests should be performed such as 
gene expression of specific osteoclastic markers.  
 
 
 
 
 
 
 
 
 
Fig.  15. TRAP Staining performed in samples. Arrows are pointing to 
osteoclasts which are on the surface of the scaffold (A) and in the bottom 
of the well (B) 
A B 
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Fig.  16. TRAP Staining performed on samples. Arrows showing 
osteoclasts in the surface of the scaffold (image A in detail) 
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DISCUSSION  
 
  Bone regeneration and ARP could be achieved through application of several materials, 
isolated or combined, in bone defects. In what concerns socket filling, the grafting material should 
present some essential properties: allow the maintenance of the space without affecting the normal 
healing process, present osteoconduction with formation of dense bone (1-3, 8, 9), which allow 
stability of  the implants, resorption of the material should occur with its substitution for bone, 
availability, safety and relatively inexpensive (1, 8, 9). We should take in consideration the 
association between the sequence of the treatment and the resorption rate of the material (1, 2, 9). 
Slow resorbing materials maintain its presence for a long time and allow new bone formation (3, 
7). 
CB is formed by two different parts (16, 21). The dorsal shield which is the thick external 
wall and the other part is the internal lamellar matrix, an extremely porous parallel structure in 
which the different sheets distance from each other 200-600 𝜇𝑚 (16, 21). Ideal pore size (80 𝜇𝑚 
in width and 100 𝜇𝑚 in height) and interconnectivity presented by CBSHA seem to support and 
promote vascularization and the growth of hard and soft tissues (24, 27). The possibility to obtain 
HA from CB aragonite through hydrothermal reaction associated to the maintenance of the porous 
architecture with low cost and availability, has led investigations to its application in bone 
preserving and regenerating processes (16, 27, 31).  
Over the last decades, human activities have been introducing several pollutants in marine 
ecosystems (16, 40). Heavy metals are an important group of environmental pollutants (40, 41), 
commonly found in waste water (16, 40). CB presents a strong capacity for bioaccumulation of 
several contaminants, such as metals, in their tissues (16, 34, 41-44). A high removal capacity for 
divalent heavy metal ions (such as Pb, Zn, Cu, Cd, Co and Sb) from water is also presented by HA 
(16, 45-50). Therefore, given the biological origin of HA produced from cuttlebone, whose marine 
habitat has heavy metals, doubts arise as to the amount of these metals that may be present in the 
product of the reaction, as well as the risk that these metals may cause when implanting the 
material in the human bone and its possible migration to the biological medium. 
Testing the material in cell culture is essential for the establishment of viability, 
cytotoxicity, adhesion, proliferation and migration of the cells in scaffolds.  
The viability values shown that scaffolds allowed viability of the cells, presenting levels of 
cell metabolic activity similar to 2D. In literature, viability was analysed using different techniques 
but the analysis through resazurin assay was not found. 
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Biocompatibility results shown that CBSM and CBSHAM increased cells metabolic 
activity which could be explained by the fact that if heavy metals are present in the medium, their 
concentration is considered non-toxic to the cells. However, cellular activity could be stimulated 
and increased by the presence of some heavy metals and/or calcium dissolved from the CB 
scaffolds (51). Therefore, more experiments are essential to prove scaffold’s biocompatibility and 
to quantify the type and the amount of these metals. In literature, no articles were found testing 
biocompatibility of this material through elution method. 
The quantification of heavy metals in the scaffolds before and after HT were performed in 
recent master’s dissertation (16). Several metals were found with Pb presenting the highest values 
(over the recommended levels) (16). Cu, Hg and Cd were found in the range of recommended 
levels but regarding the parenteric administration only Cd is over the stablished values (16). The 
HT process seems to be favourable to the different values analysed specially in the decrease of Pb 
levels (16). 
 Actin Staining proved cells adherence to the scaffolds and the viability of the cells in the 
scaffolds. The migration of the cells was observed with this staining, showing cells distribution 
through different sheets of the scaffolds. The referred staining was not performed in other studies 
with CB. 
ALP activity revealed that scaffolds allowed the development of osteogenic differentiation. 
However, the differences between CBS and CBSHA are not significantly to allow any illation 
since the results are not quantitative. Quantitative gene expression studies may reveal subtle 
differences between materials. The results also suggest that the scaffold without OS supplements 
may promote osteogenic differentiation since a certain degree of ALP activity was observed in 
control scaffolds.  
Hongmin et al. (24) quantified ALP activity and observed an increase of it in CBS and 
CBSHA during 13 days with 35.4% higher activity on CBSHA than on CBS. Rocha et al. (27, 28) 
shown that CB provided scaffolds that enhanced osteoblasts viability presenting ALP values 
similar to the control. 
TRAP Staining showed that osteoclastogenesis possibly occurred in the surface of the 
scaffolds. However, would be interesting to evaluate the osteoclast activity into the scaffolds. 
Studies with osteoclast applied to CB were not found.  
Several studies tested structural and chemical modifications in CB in order to improve cell 
growth and proliferation, compressive strength (22, 25, 29, 35), reduce the kinetics and the yield 
of the reaction (33). 
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Some in vivo studies have been described using CB scaffolds.  
Hongmin et al. (24) tested CBS and CBSHA in dorsal subcutaneous pockets of mice and 
observed that blood invasion occurred and new bone was formed in a CBSHA in contrast with 
CBS in which no bone was formed. 
Li et al. (23) implanted CBSHA, with different times of HT, into rabbit femurs. The results 
showed that biocompatibility and slowly absorption of the scaffolds with new bone formation, due 
to the osteoblasts infiltration.  
Nevertheless, more studies in vivo are necessary before testing the material in Humans. 
Using a model which could simulate the human oral cavity conditions is required to conclude the 
effect of this biomaterial in ARP and in bone regeneration.  
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CONCLUSIONS 
 
In this study, CBS and CBSHA obtained from Sepia officinalis exhibit biocompatibility 
allowing cells adhesion, proliferation and differentiation. The worldwide availability, low cost 
production and the easy machining to obtain ideal shapes for each demand are some of the few 
characteristics that make this material so unique. Osteoinductive capacity associated to chemical 
and structural characteristics of CB appoints it to be an excellent candidate for ARP. Nevertheless, 
the major disadvantage of CBSHA is its brittleness.  
In future works, would be interesting evaluate the material response in osteoblast and 
osteoclast co-cultures and its application in vivo, with a model, which could simulate the human 
oral cavity. 
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APPENDICES 
 
Appendix I – Declaração de autorização da Direcção Geral de Alimentação e Veterinária 
 
Exmo.(s) Senhor(es), 
  Relativamente ao pedido de autorização que nos foi formulado para a recolha, transporte e 
utilização de subprodutos animais de categoria 3, provenientes de peixarias locais da cidade de 
Aveiro, nomeadamente, osso/casca de choco para fins específicos de investigação no Instituto 
Nacional de Engenharia Biomédica da Universidade do Porto, informa-se V.ª Ex.ª, que ao abrigo 
do disposto no Artigo 17.º do Regulamento (CE) n.º 1069/2009 de 21 de Outubro, pode ser 
autorizado o manuseamento e utilização de subprodutos animais de categoria 3, destinados a fins 
de investigação, desde que, para garante do controlo dos riscos para a saúde pública e animal, 
sejam cumpridas as seguintes condições: 
• O operador dos subprodutos animais para diagnóstico e investigação, deve tomar todas as 
medidas necessárias para evitar a propagação de doenças transmissíveis aos seres humanos ou 
aos animais durante o manuseamento das matérias sob a sua responsabilidade, sobretudo através 
da aplicação de boas práticas de laboratório. 
• É proibida qualquer utilização subsequente dos subprodutos animais, para outros fins que não 
o exame no âmbito das atividades autorizadas. 
• O transporte até ao destino final deve ser efetuado em embalagem, veículo ou contentor 
adequado para o efeito e identificado com a menção «Categoria 3 – Destinados à investigação e 
ao diagnóstico»; 
• A menos que sejam conservadas para efeitos de referência, as amostras para diagnóstico e 
investigação, e quaisquer produtos derivados da utilização dessas amostras, devem ser 
eliminados: 
a) Como resíduos, por incineração ou coincineração; 
b) No caso dos subprodutos animais ou produtos derivados referidos no artigo 8.º, 
alínea a), subalínea iv), no artigo 8.º, alínea c) e alínea d), no artigo 9.º  e no 
artigo 10.º do Regulamento (CE) n.º 1069/2009 que fazem parte de culturas de 
células, kits de laboratório ou amostras de laboratório, através de um tratamento 
em condições que são pelo menos equivalentes ao método validado para 
autoclaves a vapor[1] e subsequente eliminação como resíduos ou águas 
residuais, em conformidade com a legislação pertinente da União. 
     [1] CEN TC/102 - Esterilizadores para fins médicos - EN 285:2006 + A2:2009 - Esterilização 
– Esterilizadores a vapor – Grandes esterilizadores; referência publicada no JO C 293 de 
2.12.2009, p. 39. 
c)  Por esterilização sob pressão e subsequente eliminação ou utilização, em 
conformidade com os artigos 12.º, 13.º e 14.º do Regulamento (CE) n.º 1069/2009. 
• O utilizador deve proceder a um registo datado dos subprodutos animais utilizados, que deve 
especificar a descrição das matérias, espécie animal, categoria, quantidade, data, local de origem, 
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nome do expedidor, nome do utilizador e método de eliminação das amostras e de quaisquer 
produtos derivados. 
  Mais se informa que, nos termos do disposto na alínea a), n.º 1 do Artigo 23.º do Regulamento 
(CE) n.º 1069/2009 de 21 de Outubro, foi atribuído ao INSTITUTO NACIONAL DE 
ENGENHARIA BIOMÉDICA da UNIVERSIDADE DO PORTO, sito na Rua Alfredo Allen, 
208, 4200-135 Porto, o número de registo N.12.010.UDER, como utilizador de subprodutos 
animais de categoria 3 para fins de investigação. 
 
 Com os melhores cumprimentos, 
José M. Correia 
Eng. Téc. Agr. 
DGAV – Direção Geral de Alimentação e Veterinária 
DCCA – Divisão de Controlo da Cadeia Alimentar 
Quinta do Marquês, Av.ª República, 2780-155 Oeiras 
Tef. Geral:21 446 40 00   Tef. Secret. 21 446 40 61 
Fax: 21 446 40 99       e-mail: jmcorreia@dgav.pt 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


